QINGSONG HEALTH (02661) has announced the official integration of its self-developed artificial intelligence evidence-based medicine agent, "Zhengyuanfang," into the Group's professional service platform for doctors and medical professionals, "Yilu Qingsong." This marks a product-level integration of the Group's proprietary medical AI capabilities with its own physician service network. "Zhengyuanfang" is an evidence-based medicine agent designed around evidence-based methodology. Tailored for real clinical scenarios, it provides doctors with explainable, verifiable, and traceable medical decision support, elevating AI from a "medical Q&A tool" to an "evidence-based decision assistant."
According to the Group's internal statistics as of March 31, 2026, the number of medical professional users on the "Yilu Qingsong" platform empowered by "Zhengyuanfang" reached 69,615, representing a 46.4% increase from the 47,554 users recorded as of March 31, 2025. Specifically, the number of ophthalmology professionals reached 3,672, a 171.0% increase from 1,355 a year earlier. Furthermore, the number of associate chief physicians and above reached 36,678, accounting for approximately 52.7% of the platform's total medical professional users, a 42.7% increase from 25,701 as of March 31, 2025.
The Board believes that the integration of "Zhengyuanfang" into "Yilu Qingsong" signifies that the Group has established a synergistic framework combining its self-developed evidence-based medicine AI capabilities with a scalable physician service network. This allows the Group's leading evidence-based AI capabilities to directly serve the clinical decision-making and professional development needs of frontline medical professionals. The continuous expansion of the platform's medical professional user base, particularly with over half being associate chief physicians and above, reflects the strong user structure and professional depth of the Group's digital services for medical professionals.
The Board is confident that these developments lay a solid foundation for the Group's sustained growth in the fields of evidence-based medicine assistance, digital services for medical professionals, and AI-driven professional health intelligence services. Currently, QINGSONG HEALTH has established a clear and structured three-tier AI framework based on its self-developed AIcare technology stack: 1. Foundation Layer: The Nebula Digital Base, providing AI infrastructure capabilities for all business scenarios. 2. Core Model: The Dr. GPT specialized medical large language model, supporting the intelligentization of comprehensive health services across the ecosystem. 3. Vertical Agent Applications: The Zhengyuanfang series of evidence-based medicine agent products, focusing on evidence-based medicine scenarios for professional doctors, enabling the extension of the Group's AI capabilities from general health services to serious medical fields.
Leveraging the core technological advantages of the AIcare stack, the Group will continue to focus on vertical scenarios within the healthcare sector. It will deepen the development and practical application of AI agents in areas such as evidence-based medicine, clinical decision support, physician services, and public health management. This aims to build a comprehensive AI service matrix covering both professional and user ends, steadily advancing the digital and intelligent upgrade of healthcare services, and injecting sustained momentum into the Group's long-term high-quality development.
Comments